This is a Phase 3, global, randomized, open-label, multicenter, trial evaluating brelovitug (BJT-778) vs bulevirtide for the treatment of chronic hepatitis delta infection (CHD). The main goal of this study is to test the effectiveness of brelovitug compared to bulevirtide as a long-term treatment in patients with chronic HDV infection.
Willing and able to provide written informed consent
Chronic HDV infection
HDV RNA >500 IU/mL at Screening
ALT >ULN at Screening
Pregnant or nursing females
Unwilling to comply with contraception requirements during the study
Difficulty with blood collection and/or poor venous access for the purposes of phlebotomy
Clinical hepatic decompensation (i.e., ascites, encephalopathy variceal hemorrhage).
Mirum Pharmaceuticals, Inc.
Lead sponsor